ProfileGDS5678 / 1460614_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 81% 78% 81% 79% 83% 81% 83% 82% 80% 81% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8506682
GSM967853U87-EV human glioblastoma xenograft - Control 25.787881
GSM967854U87-EV human glioblastoma xenograft - Control 35.8275681
GSM967855U87-EV human glioblastoma xenograft - Control 45.4724678
GSM967856U87-EV human glioblastoma xenograft - Control 55.7691481
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3236179
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.93583
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.833381
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0814683
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9286882
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6865380
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.821781
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7324781
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7627381